
Celine Cano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3368664/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K. Molecular Cancer Therapeutics, 2012, 11, 1789-1798.	1.9	112
2	DNA-Dependent Protein Kinase Is a Therapeutic Target and an Indicator of Poor Prognosis in B-Cell Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2008, 14, 3984-3992.	3.2	89
3	Identification and Characterization of an Irreversible Inhibitor of CDK2. Chemistry and Biology, 2015, 22, 1159-1164.	6.2	85
4	Pyranone, Thiopyranone, and Pyridone Inhibitors of Phosphatidylinositol 3-Kinase Related Kinases. Structureâ^'Activity Relationships for DNA-Dependent Protein Kinase Inhibition, and Identification of the First Potent and Selective Inhibitor of the Ataxia Telangiectasia Mutated Kinase. Journal of Medicinal Chemistry, 2007, 50, 1958-1972.	2.9	79
5	Cyclin-Dependent Kinase (CDK) Inhibitors: Structure–Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines. Journal of Medicinal Chemistry, 2017, 60, 1746-1767.	2.9	77
6	Targeting DNAâ€Dependent Protein Kinase for Cancer Therapy. ChemMedChem, 2017, 12, 895-900.	1.6	63
7	FragLites—Minimal, Halogenated Fragments Displaying Pharmacophore Doublets. An Efficient Approach to Druggability Assessment and Hit Generation. Journal of Medicinal Chemistry, 2019, 62, 3741-3752.	2.9	62
8	Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination. Cancer Chemotherapy and Pharmacology, 2012, 69, 155-164.	1.1	55
9	1-Substituted (Dibenzo[<i>b,d</i>]thiophen-4-yl)-2-morpholino-4 <i>H</i> -chromen-4-ones Endowed with Dual DNA-PK/PI3-K Inhibitory Activity. Journal of Medicinal Chemistry, 2013, 56, 6386-6401.	2.9	45
10	Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy. Journal of Clinical Investigation, 2019, 130, 258-271.	3.9	45
11	DNA-Dependent Protein Kinase (DNA-PK) Inhibitors. Synthesis and Biological Activity of Quinolin-4-one and Pyridopyrimidin-4-one Surrogates for the Chromen-4-one Chemotype. Journal of Medicinal Chemistry, 2010, 53, 8498-8507.	2.9	40
12	Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer. British Journal of Cancer, 2016, 115, 682-690.	2.9	40
13	Recent advances in CDK inhibitors for cancer therapy. Future Medicinal Chemistry, 2018, 10, 1369-1388.	1.1	35
14	Trifluoroacetic Acid in 2,2,2â€Trifluoroethanol Facilitates S _N Ar Reactions of Heterocycles with Arylamines. Chemistry - A European Journal, 2014, 20, 2311-2317.	1.7	32
15	Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction. Journal of Medicinal Chemistry, 2021, 64, 4071-4088.	2.9	30
16	Structural insights into the enzymatic activity and potential substrate promiscuity of human 3-phosphoglycerate dehydrogenase (PHGDH). Oncotarget, 2017, 8, 104478-104491.	0.8	27
17	8-Biarylchromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK). Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4885-4890.	1.0	26
18	Synthesis and biological evaluation of 5-substituted O4-alkylpyrimidines as CDK2 inhibitors. Organic and Biomolecular Chemistry, 2010, 8, 2397.	1.5	26

CELINE CANO

#	Article	IF	CITATIONS
19	Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer. Oncotarget, 2018, 9, 13139-13153.	0.8	25
20	Quinolinone and pyridopyrimidinone inhibitors of DNA-dependent protein kinase. Organic and Biomolecular Chemistry, 2007, 5, 2670.	1.5	23
21	Human Toxicity Caused by Indole and Indazole Carboxylate Synthetic Cannabinoid Receptor Agonists: From Horizon Scanning to Notification. Clinical Chemistry, 2018, 64, 346-354.	1.5	23
22	Mapping the ATP-binding domain of DNA-dependent protein kinase (DNA-PK) with coumarin- and isocoumarin-derived inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 3649-3653.	1.0	21
23	DNA-dependent protein kinase (DNA-PK) inhibitors: Structure–activity relationships for O-alkoxyphenylchromen-4-one probes of the ATP-binding domain. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 966-970.	1.0	21
24	Potent enantioselective inhibition of DNA-dependent protein kinase (DNA-PK) by atropisomeric chromenone derivatives. Organic and Biomolecular Chemistry, 2012, 10, 6747.	1.5	21
25	The discovery of potent ribosomal S6 kinase inhibitors by high-throughput screening and structure-guided drug design. Oncotarget, 2013, 4, 1647-1661.	0.8	20
26	Identification of dual DNA-PK MDR1 inhibitors for the potentiation of cytotoxic drug activity. Biochemical Pharmacology, 2014, 88, 58-65.	2.0	18
27	Model system for irreversible inhibition of Nek2: thiol addition to ethynylpurines and related substituted heterocycles. Organic and Biomolecular Chemistry, 2014, 12, 141-148.	1.5	18
28	High-Throughput Screening and Hit Validation of Extracellular-Related Kinase 5 (ERK5) Inhibitors. ACS Combinatorial Science, 2016, 18, 444-455.	3.8	18
29	A bis(η5-cyclopentadienyl)cobalt complex of a bis-dithiolene: a chemical analogue of the metal centres of the DMSO reductase family of molybdenum and tungsten enzymes, in particular ferredoxin aldehyde oxidoreductase. Tetrahedron, 2005, 61, 11010-11019.	1.0	17
30	Regio- and Enantioselective Synthesis of Novel Functionalized PyranoÂpyrrolidines by 1,3-Dipolar Cycloaddition of Carbohydrates. Synlett, 2005, 2005, 587-590.	1.0	16
31	Atropisomeric 8-arylchromen-4-ones exhibit enantioselective inhibition of the DNA-dependent protein kinase (DNA-PK). Organic and Biomolecular Chemistry, 2010, 8, 1922.	1.5	16
32	8-Substituted <i>O</i> ⁶ -Cyclohexylmethylguanine CDK2 Inhibitors: Using Structure-Based Inhibitor Design to Optimize an Alternative Binding Mode. Journal of Medicinal Chemistry, 2014, 57, 56-70.	2.9	15
33	Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach. Organic and Biomolecular Chemistry, 2018, 16, 1843-1850.	1.5	15
34	Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4. European Journal of Medicinal Chemistry, 2019, 178, 530-543.	2.6	15
35	Structure-guided design of purine-based probes for selective Nek2 inhibition. Oncotarget, 2017, 8, 19089-19124.	0.8	13
36	Nek7 conformational flexibility and inhibitor binding probed through protein engineering of the R-spine. Biochemical Journal, 2020, 477, 1525-1539.	1.7	12

CELINE CANO

#	Article	IF	CITATIONS
37	Versatile synthesis of functionalised dibenzothiophenes via Suzuki coupling and microwave-assisted ring closure. Organic and Biomolecular Chemistry, 2011, 9, 6066.	1.5	11
38	Trifluoroethanol solvent facilitates selective N-7 methylation of purines. Organic and Biomolecular Chemistry, 2013, 11, 1874.	1.5	10
39	An Alkynylpyrimidine-Based Covalent Inhibitor That Targets a Unique Cysteine in NF-κB-Inducing Kinase. Journal of Medicinal Chemistry, 2021, 64, 10001-10018.	2.9	9
40	Chronic glucokinase activator treatment activates liver Carbohydrate response element binding protein and improves hepatocyte <scp>ATP</scp> homeostasis during substrate challenge. Diabetes, Obesity and Metabolism, 2020, 22, 1985-1994.	2.2	8
41	2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase. RSC Medicinal Chemistry, 2020, 11, 707-731.	1.7	8
42	Stereoselective Cycloaddition on Carbohydrates for the Synthesis of New Bicyclic Oxazolidines Bearing a Quaternary Bridgehead. Synlett, 2005, 2005, 1425-1428.	1.0	7
43	Synthesis and Biological Evaluation of N2-Substituted 2,4-Diamino-6-cyclohexylmethoxy-5-nitrosopyrimidines and Related 5-Cyano-NNO-azoxy Derivatives as Cyclin-Dependent Kinaseâ€2 (CDK2) Inhibitors. ChemMedChem, 2016, 11, 1705-1708.	1.6	6
44	Concise syntheses of bridged morpholines. RSC Advances, 2016, 6, 53955-53957.	1.7	5
45	Design and synthesis of biphenyl and biphenyl ether inhibitors of sulfatases. Chemical Science, 2016, 7, 2821-2826.	3.7	5
46	A new tool for the chemical genetic investigation of the Plasmodium falciparum Pfnek-2 NIMA-related kinase. Malaria Journal, 2016, 15, 535.	0.8	4
47	Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor. Journal of Medicinal Chemistry, 2022, 65, 6513-6540.	2.9	3
48	Synthesis of 3â€2-deoxy-3â€2-fluorothymidine (FLT) 5â€2-O-glucuronide: a reference standard for imaging studies with [¹⁸ F]FLT. MedChemComm, 2014, 5, 984-988.	3.5	1
49	Inhibition of the DNA-Dependent Protein Kinase for Cancer Therapy. , 2017, 07, .		1
50	Regio- and Enantioselective Synthesis of Novel Functionalized Pyranopyrrolidines by 1,3-Dipolar Cycloaddition of Carbohydrates ChemInform, 2005, 36, no.	0.1	0
51	Stereoselective Cycloaddition on Carbohydrates for the Synthesis of New Bicyclic Oxazolidines Bearing a Quaternary Bridgehead ChemInform, 2005, 36, no.	0.1	0
52	Modulation of the DNA-Damage Response by Inhibitors of the Phosphatidylinositol 3-Kinase Related Kinase (PIKK) Family. Topics in Medicinal Chemistry, 2017, , 189-189.	0.4	0
53	Targeting DNA-PK as a Therapeutic Approach in Oncology. Cancer Drug Discovery and Development, 2018, , 339-357.	0.2	0
54	Molecular dynamics simulations reveal the determinants of cyclin-dependent kinase 2 inhibition by 5-nitrosopyrimidine derivatives. Journal of Biomolecular Structure and Dynamics, 2020, 38, 4016-4024.	2.0	0

#	Article	IF	CITATIONS
55	Cyclizations and fragmentations in the alkylation of 6â€chloroâ€5â€hydroxyâ€4â€aminopyrimidines with aminoalkyl chlorides. Journal of Heterocyclic Chemistry, 2021, 58, 947-951.	1.4	0